|
EP1528101A1
(en)
*
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
|
US20070207461A1
(en)
|
2004-02-23 |
2007-09-06 |
Crucell Holland B.V. |
Virus Purification Methods
|
|
CA2602944C
(en)
|
2005-04-11 |
2015-08-11 |
Crucell Holland B.V. |
Virus purification using ultrafiltration
|
|
DE102005054628A1
(de)
|
2005-11-16 |
2007-05-24 |
Cevec Pharmaceuticals Gmbh |
Verfahren zur Herstellung von permanenten humanen Zelllinien
|
|
SI2061803T2
(sl)
|
2006-08-28 |
2023-01-31 |
Ares Trading S.A. |
Postopek za čiščenje proteinov, ki vsebujejo FC
|
|
US10041049B2
(en)
|
2008-11-03 |
2018-08-07 |
Janssen Vaccines & Prevention B.V. |
Method for the production of adenoviral vectors
|
|
DE102009003439A1
(de)
|
2009-02-05 |
2010-08-26 |
Cevec Pharmaceuticals Gmbh |
Neue permanente humane Zelllinie
|
|
CA2777116C
(en)
|
2009-10-15 |
2020-09-01 |
Crucell Holland B.V. |
Process for adenovirus purification from high cell density cultures
|
|
JP5393896B2
(ja)
|
2009-10-15 |
2014-01-22 |
クルセル ホランド ベー ヴェー |
アデノウイルス粒子の精製方法
|
|
MX2012007936A
(es)
|
2010-02-15 |
2012-11-22 |
Crucell Holland Bv |
Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
|
|
EP2606128B1
(de)
|
2010-08-16 |
2014-09-10 |
CEVEC Pharmaceuticals GmbH |
Permanente humane amniozyten zellinie zur herstellung von influenzaviren
|
|
KR101427200B1
(ko)
*
|
2011-11-24 |
2014-08-07 |
주식회사 바이로메드 |
아데노바이러스 생산 신규 세포주 및 그의 용도
|
|
SI2825640T1
(sl)
|
2012-03-12 |
2016-08-31 |
Crucell Holland B.V. |
Šarže rekombinantnega adenovirusa s spremenjenimi konci
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
JP5805908B2
(ja)
|
2012-03-22 |
2015-11-10 |
クルセル ホランド ベー ヴェー |
Ｒｓｖに対するワクチン
|
|
EP2662451A1
(en)
|
2012-05-07 |
2013-11-13 |
Stefan Kochanek |
Nucleic acid construct and use of the same
|
|
WO2014060594A1
(en)
*
|
2012-10-19 |
2014-04-24 |
Cevec Pharmaceuticals Gmbh |
Production of a hcmv based vaccine in human amniocyte cell lines
|
|
EP2722337A1
(en)
|
2012-10-19 |
2014-04-23 |
CEVEC Pharmaceuticals GmbH |
Production of a HCMV based vaccine in human amniocyte cell lines
|
|
KR102236497B1
(ko)
|
2013-04-25 |
2021-04-06 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
|
|
CN105408348B
(zh)
|
2013-06-17 |
2021-07-06 |
扬森疫苗与预防公司 |
稳定化的可溶性融合前rsv f多肽
|
|
DE112014003136A5
(de)
|
2013-07-01 |
2016-04-21 |
Charité - Universitätsmedizin Berlin |
Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen
|
|
RS58080B1
(sr)
|
2014-11-04 |
2019-02-28 |
Janssen Vaccines & Prevention Bv |
Terapeutske vakcine protiv hpv16
|
|
EP3042952A1
(en)
|
2015-01-07 |
2016-07-13 |
CEVEC Pharmaceuticals GmbH |
O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
|
|
JP6735288B2
(ja)
|
2015-04-14 |
2020-08-05 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
|
|
EA039065B1
(ru)
|
2015-07-07 |
2021-11-29 |
Янссен Вэксинс Энд Превеншн Б.В. |
Вакцина против rsv
|
|
US10457708B2
(en)
|
2015-07-07 |
2019-10-29 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
|
JP6470872B2
(ja)
|
2015-08-20 |
2019-02-13 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
治療用ｈｐｖ１８ワクチン
|
|
JP7233928B2
(ja)
|
2016-04-05 |
2023-03-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Ｒｓｖに対するワクチン
|
|
IL262108B2
(en)
|
2016-04-05 |
2023-04-01 |
Janssen Vaccines Prevention B V |
Soluble pre-fusion rsv f proteins are stabilized
|
|
JP7053491B2
(ja)
|
2016-05-02 |
2022-04-12 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
治療用ｈｐｖワクチン組み合わせ
|
|
CN109154000B
(zh)
|
2016-05-12 |
2022-07-05 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
|
CN109311946A
(zh)
|
2016-05-30 |
2019-02-05 |
扬森疫苗与预防公司 |
稳定化的融合前rsv f蛋白
|
|
RU2745500C2
(ru)
|
2016-06-20 |
2021-03-25 |
Янссен Вэксинс Энд Превеншн Б.В. |
Эффективный и сбалансированный двунаправленный промотор
|
|
WO2018011196A1
(en)
|
2016-07-14 |
2018-01-18 |
Janssen Vaccines & Prevention B.V. |
Hpv vaccines
|
|
US11034978B2
(en)
|
2017-02-09 |
2021-06-15 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
|
EP3382014A1
(en)
|
2017-03-29 |
2018-10-03 |
CEVEC Pharmaceuticals GmbH |
Recombinant glycoproteins with reduced antennary fucosylation
|
|
AU2018267971A1
(en)
|
2017-05-17 |
2019-11-07 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
|
SG11202001458SA
(en)
|
2017-09-15 |
2020-03-30 |
Janssen Vaccines & Prevention Bv |
Method for the safe induction of immunity against rsv
|
|
WO2019086466A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
WO2019086461A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
|
WO2019086450A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
CN111372943B
(zh)
|
2017-10-31 |
2023-12-05 |
扬森疫苗与预防公司 |
腺病毒及其用途
|
|
MX2021005607A
(es)
|
2018-11-13 |
2021-06-30 |
Janssen Vaccines & Prevention Bv |
Proteinas f de prefusion del vrs estabilizadas.
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
EP3736286A1
(en)
|
2019-05-09 |
2020-11-11 |
Biotest AG |
Single chain factor viii molecule
|
|
JP2022532742A
(ja)
|
2019-05-15 |
2022-07-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
|
|
WO2020229577A1
(en)
|
2019-05-15 |
2020-11-19 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
|
EP4017521A1
(en)
|
2019-09-02 |
2022-06-29 |
Biotest AG |
Factor viii protein with increased half-life
|
|
EP3785726A1
(en)
|
2019-09-02 |
2021-03-03 |
Biotest AG |
Factor viii protein with increased half-life
|
|
US20220372515A1
(en)
|
2019-10-03 |
2022-11-24 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
|
CR20220220A
(es)
|
2019-11-18 |
2022-09-20 |
Janssen Biotech Inc |
Vacunas basadas en calr y jak2 mutantes y sus usos
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
US20230190881A1
(en)
|
2020-02-17 |
2023-06-22 |
Biotest Ag |
Subcutaneous administration of factor viii
|
|
US20230024133A1
(en)
|
2020-07-06 |
2023-01-26 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
|
US20230035403A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Method For Determining Responsiveness To Prostate Cancer Treatment
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4229204A1
(en)
|
2020-10-15 |
2023-08-23 |
F. Hoffmann-La Roche AG |
Nucleic acid constructs for simultaneous gene activation
|
|
CA3197730A1
(en)
|
2020-10-15 |
2022-04-21 |
F. Hoffman-La Roche Ag |
Nucleic acid constructs for va rna transcription
|
|
TW202323529A
(zh)
|
2021-10-18 |
2023-06-16 |
美商再生元醫藥公司 |
包括腺病毒相關病毒聚核苷酸的真核細胞
|
|
EP4508241A1
(en)
|
2022-04-13 |
2025-02-19 |
F. Hoffmann-La Roche AG |
Method for determining aav genomes
|
|
CN119256220A
(zh)
|
2022-05-23 |
2025-01-03 |
豪夫迈·罗氏有限公司 |
用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法
|
|
CN119301260A
(zh)
|
2022-06-03 |
2025-01-10 |
豪夫迈·罗氏有限公司 |
用于生产重组aav颗粒的方法
|
|
KR20250036743A
(ko)
|
2022-07-14 |
2025-03-14 |
에프. 호프만-라 로슈 아게 |
재조합 aav 입자를 생산하는 방법
|
|
CA3264505A1
(en)
|
2022-09-12 |
2024-03-21 |
F. Hoffmann-La Roche Ag |
METHOD FOR SEPARING SOLID AND EMPTY VAA PARTICLES
|
|
AU2024216670A1
(en)
|
2023-02-07 |
2025-07-31 |
F. Hoffmann-La Roche Ag |
Method for the detection of anti-aav particle antibodies
|
|
AU2024239386A1
(en)
|
2023-03-21 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for the production of recombinant aav particle preparations
|
|
CN117487761A
(zh)
*
|
2023-09-25 |
2024-02-02 |
南京农业大学 |
表达Cre基因猪骨髓巨噬细胞系的构建方法及其应用
|
|
WO2025158316A1
(en)
|
2024-01-26 |
2025-07-31 |
Janssen Biotech, Inc. |
Ovarian neoantigens and use thereof
|
|
WO2025168663A1
(en)
|
2024-02-09 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant adeno-associated viral particles
|
|
WO2025252480A1
(en)
|
2024-06-07 |
2025-12-11 |
F. Hoffmann-La Roche Ag |
Method for purifying plasmid dna
|
|
WO2026022064A1
(en)
|
2024-07-22 |
2026-01-29 |
F. Hoffmann-La Roche Ag |
Novel aav rep orfs and rep polypeptides
|
|
WO2026037757A1
(en)
|
2024-08-13 |
2026-02-19 |
F. Hoffmann-La Roche Ag |
Modified aav particles
|